1. Overview
In the first half of 22, the COVID-19 epidemic swept the world, causing unprecedented impacts on all countries and industries in the world, and at the same time having a positive impact on the development of the pharmaceutical industry. In the process of fighting the epidemic, Chinese medicine has played an important role, and many kinds of Chinese medicines have been officially included in the diagnosis and treatment programs at all levels. The observation of clinical efficacy shows that the total effective rate of Chinese medicine in the application process of epidemic prevention and control has reached more than 9%. The remarkable role of Chinese medicine in fighting the epidemic situation is conducive to enhancing the strategic position and social recognition of Chinese medicine in China and promoting the internationalization of Chinese medicine. At the same time, the government's concept of "from treating diseases to preventing diseases without diseases" will also lead the national health consumption to a more mature stage, and the big health industry will usher in a major development opportunity. On the other hand, the reform of the medical system continues to deepen, the consistency evaluation of injections is started, the national centralized drug procurement is normalized, the medical security system, the drug management system and other medical policies are intensively introduced, and the pharmaceutical industry will still be in the adjustment stage, the competition in the industry will be further intensified, and the industry concentration will continue to increase.
facing the challenges and opportunities, while inheriting the traditional Chinese medicine theory, culture and medical technology, the company adheres to the development concept of "combining inheritance with innovation", practices the mission of "serving great health through a hundred years", integrates traditional medicine with modern medicine, and arranges the business of stem cell medicine industry and medicine and food homologous series products. At the same time, it conforms to the national policy orientation of vigorously developing Internet medical care. Relying on "internet plus Traditional Chinese Medicine", we explored and promoted the Internet hospital project, and put it into trial operation one after another, aiming at providing accurate and effective services for human life-cycle health management from three areas of prevention, treatment and rehabilitation, and creating a healthy and beautiful life for human beings.
during the reporting period, the company "nurtured new opportunities in the crisis and opened new opportunities in the changing situation", strengthened its cultural confidence, strategic confidence and road confidence, deepened the group's management and control mode, continuously cultivated the core advantages of traditional businesses, rapidly promoted the steady development of innovative businesses, and actively carried out various tasks around the annual business work plan, with good overall production and operation conditions.
in terms of production, the company adheres to the normal management of epidemic prevention and control, and the ability of epidemic prevention and control and production management have been continuously improved. The overall production and epidemic prevention and control of the company are safe and stable, and all employees are free from infection; In terms of operation, the company gives full play to the locomotive role of the market, takes sales as the core, taps the potential of existing varieties, and ensures that traditional products are better and stronger; In terms of innovation, the company intensively laid out stem cell business, followed the trend to explore new Internet business models, accelerated the development direction of large health products with homology of medicine and food, actively promoted the breakthrough of innovative projects, and ensured the company's sustainable development in the future.
in the first half of 22, the company achieved an operating income of 1,832,973,6 yuan, up 8.55% year-on-year, and a net profit attributable to shareholders of listed companies of 197,115, yuan, up 11.71% year-on-year.
during the reporting period, the company mainly carried out the following work:
1. Actively promote the re-evaluation of the listed products and improve the competitiveness of the products
1.1 Evidence-based medicine and re-evaluation project of Shuxuetong injection in Youbo Pharmaceutical
During the reporting period, the research group of Evidence-based Medicine Clinical Research on Shuxuetong Injection (SPACE), a major special project in the Twelfth Five-Year Plan, held a special discussion, and the test results showed that Shuxuetong injection was effective in determining embolism. At the "12th Healthy China Forum Parallel Forum on Evidence-based Chinese Medicine" sponsored by People's Daily, People's Daily Health Client and Health Times, Shuxuetong Injection was rated as the first in the "Evidence-based Evaluation Index TOP1 of Chinese Patent Medicines (Stroke)" by the Evidence-based Chinese Medicine Research Alliance. This is the first authoritative evaluation of the clinical value of Chinese patent medicines from the perspective of evidence-based medicine. According to the analysis method of clinical evidence index of Chinese patent medicines, according to the quantity, quality and expert knowledge of clinical research,
during the reporting period, the re-evaluation of Shuxuetong injection initiated by the company progressed steadily. Experiments related to the safety re-evaluation of Shuxuetong injection have been carried out continuously, and the group labels of leeches and lumbricus have passed the project review of the Standardization Office of Chinese Medicine Association; Relying on the project "Study on Material Basis and Mechanism of Shuxuetong Injection" carried out by Tianjin University of Traditional Chinese Medicine, 6 academic articles have been published and 8 patent applications have been filed. This work has laid a solid foundation for continuously improving the clinical value of Shuxuetong injection, the leading variety of the company, and effectively carrying out professional academic promotion.
1.2 siqikang standard improvement project
during the reporting period, the standard improvement project of BCG polysaccharide nucleic acid injection (siqikang) carried out by the company completed the separation, purification, component analysis and sequencing of nucleic acid components, the stimulation experiment of nucleic acid immune factor TNF-α, the chemical structure analysis of polysaccharide, the efficacy test, etc., which laid the foundation for reasonably explaining the material basis and mechanism of siqikang and establishing a highly specific quality standard.
2. Focus on drug research and development, and accelerate innovative projects
2.1 LFG project, a new anticoagulant drug
During the reporting period, the LFG project completed the stability study of LFG preparations and raw materials (pilot samples), followed by the pre-clinical safety test, ready to start the related work of IND declaration. In the first half of 22, the LFG project added two invention patents, including one in the United States. By the end of the reporting period, the project had obtained 15 patent authorization certificates distributed in seven countries.
2.2 stem cell project
During the reporting period, Beijing Meike successively won the title of "the ninth batch of golden seed enterprises" by the Zhongguancun Science Park Management Committee, the financial support from Daxing District to promote the development of medicine and health industry, and the qualification of supporting unit of the Beijing Natural Science Foundation project. While it was recognized by government agencies and industries, it also made many important progress in its business.
2.2.1 Construction of production R&D base and process quality system
During the reporting period, Beijing Meike's production and R&D base in Daxing District entered the stage of equipment verification, debugging and confirmation, and related work has been basically completed. In terms of technology, Beijing Meike has conducted many batches of practical training, mastered the production process, and produced stem cells that fully meet the quality standards. In terms of quality, Beijing Meike has further improved the quality system and mastered the quality inspection technology according to the GMP requirements of China.
During the reporting period, in order to promote the clinical research and transformation of stem cells in the field of heart disease, Beijing Meike signed a Cooperation Agreement with the Second Affiliated Hospital of Harbin Medical University, and reached an agreement on the application of the two parties to the National Health and Wellness Committee for the stem cell clinical research filing project. The signing of this agreement will further promote the company to enter the field of stem cell research and enhance the company's business development space.
2.3 REMD-477 Antibody to Glucagon Receptor Project
Beijing Kexin Meide Biomedical Technology Co., Ltd., in which the company is a shareholder, mainly conducts research on REMD-477, an antibody to Glucagon Receptor. During the reporting period, REMD-477 continued its clinical phase II work and preparation work before clinical phase III in the United States. The first is to complete the long-term toxicological test of rhesus monkeys, and the formal test report is being reviewed and evaluated. The second is to complete the production and inspection of clinical samples, and to investigate the stability of clinical samples. The third is to prepare the test plan, which is currently being approved by FDA and NMPA.
2.4 intellectual property work
during the reporting period, the company * * * applied for 8 invention patents, and 7 were authorized (including 6 invention patents), mainly involving products, preparation methods, quality control methods, new uses, etc. in projects such as Callicarpa nudiflora and BCG polysaccharide nucleic acid.
3. Lean manufacturing ensures quality, and the traditional business is better and stronger
3.1OTC product management
The OTC product sales of the company rely on cultural marketing, achieving sustained and steady growth in performance. During the reporting period, the company improved and optimized the institutional system and organizational system of OTC plate, and carried out refined management of channels and terminals to ensure effective smooth channels and effective coverage of terminals. Adhere to people-oriented, cultural marketing, do a good job in strategic planning and layout of product echelon, manage by classification and classification, enlarge and strengthen strategic main products, focus on strategic new products, explore and operate project products, and focus on incubating new products with characteristics and new regulations.
At the same time, we will comprehensively strengthen consumers' traditional Chinese medicine prevention culture and health education, strengthen the cooperation between Internet digital economy and O2O new retail, and actively explore new modes such as new media and live sales.
3.2 prescription drug management
the marketing idea of "product+model+team" is clearly defined in the prescription drug sales section. During the reporting period, we overcame the impact of business resource integration, medical policy changes and epidemic situation, focused on key varieties, key markets and key terminals, adjusted the business pattern of some provinces, increased new large-scale first-class businesses, expanded terminal coverage, and comprehensively and deeply adjusted and optimized the management process to realize the whole process of business sections such as commerce, sales and market. At the same time, through the re-investigation and analysis of the market situation of the existing key products of prescription drugs, the "product academic promotion roadmap" was completed, the key markets of products were defined, the promotion plan was focused, and the implementation of academic activities was carried out. Develop new media promotion procedures and expand brand promotion and influence by building a professional academic platform. In addition, actively explore the new model of DRG promotion and commercial marketing, set up the DRG promotion department, convey the concept of rational drug use of DRG, eliminate the misunderstanding of terminal clinical use, and carry out the work of publicizing the clinical path of indications; Set up a sales team, take business as the main body, consolidate channels, segment customers and ensure sales volume by integrating resources.
3.3 pharmaceutical business
the main business of the pharmaceutical business sector has been further transformed, and the proportion of retail (including e-commerce) has gradually increased, with a certain increase in performance compared with the same period of last year. During the reporting period, in terms of chain management, 38 stores (direct stores and franchise stores) were expanded, and standardized, streamlined and digital management methods such as mobile phone inventory, remote management of ten thousand stores and supplier management system were used to strengthen franchise management, standardize store management and improve store services. Carry out new retail methods such as live broadcast and community marketing to improve the per capita efficiency level of stores.
At the same time, the store regularly carries out activities such as free clinic, social practice of primary and secondary school students and promotion of traditional Chinese medicine culture in Hunan, and actively fulfills its social responsibilities. In wholesale management, actively develop suppliers and end customers and seek new development measures to deal with the epidemic; In terms of e-commerce business, we focused on the development of O2O, achieving significant growth year-on-year.
3.4 Production Sector
During the reporting period, the production center of the headquarters of the company and its production subsidiaries overcame the difficulties caused by the COVID-19 epidemic, resumed production in an all-round way at the first time, implemented the "three guarantees" actions of ensuring price, quality and supply, promoted energy conservation and consumption reduction, advocated synergy, and carried out production work steadily. The company became the first of 623 key enterprises in Changsha High-tech Zone to recover 1% of its production capacity.
under the premise of ensuring normal production, the company steadily promotes project construction and helps upgrade and optimize the production sector. All systems of the new integrated application mode project (intelligent manufacturing project) of the company's Chinese medicine solid preparation intelligent factory have been completed. During the reporting period, they passed the national project acceptance smoothly. By promoting the intelligentization of the production process of Chinese medicine solid preparation, the intelligent management and control of the group were effectively realized, and the intelligent management level of the enterprise was comprehensively improved. The first phase of the company's Sinopharm Health Industrial Park gradually improved the construction tasks and planning and design, and held a groundbreaking ceremony during the reporting period to communicate and modify the construction drawings. Through the project construction, the category structure of Jiuzhitang fist products will be improved and a product cluster with strong competitiveness will be formed. Youbo Pharmaceutical, a wholly-owned subsidiary, carried out the work related to EU certification, and submitted the information to the EU prosecutor during the reporting period, laying the foundation for the next formal certification.
4. Innovative resources strive to break through, and new business development continues to advance
4.1 Chinese medicine medical and health service business
Chinese medicine medical and health service business takes the Internet hospital platform as the work starting point, gathers expert resources and builds product and service systems around key specialty construction, and strives to form the core competitiveness of "internet plus products+services" with specialty characteristics. Combined with offline country yiguang, the overall development idea of online and offline medical service sector operation is formulated.
during the reporting period, the company seized the opportunity that the country advocated Internet diagnosis and treatment during the COVID-19 epidemic and actively promoted the implementation of Internet hospitals. Relying on Jiuzhitang Internet Hospital established by Tianjin Old Hospital of Traditional Chinese Medicine, we obtained the practice license of medical institutions in Internet hospitals, formulated the development plan of Internet hospitals in combination with the company's superior resources, and built an online service platform closely around the core business needs. At present, we have basically completed the development of WeChat WeChat official account for patients, APP for doctors and the background, and met the business needs through internal and external testing and trial operation in Liaoning.
The company optimized the structure of China yiguang, seized the opportunity of people's health care awareness increasing after the epidemic, and explored a new mode of operation and management of Chinese Medicine Museum. The new mode of "product+service" operation of China yiguang was carried out in Zhanjiang and Beijing, and achieved certain results.
4.2 Business of medicinal and edible homologous series products
During the reporting period, the company adjusted the development strategy of medicinal and edible homologous products and the existing product specifications in a timely manner, increased the product specifications to meet the needs of the market, and focused on key products. At present, Ejiao cake, herbal tea (plant beverage), substitute tea, throat lozenge, collagen nourishing mask, essential oil soap and other products have been listed. At the same time, explore and think about the new sales cooperation mode and the path of self-supporting team construction, so as to lay the foundation for the future sales increment of medicine and food homologous series products, and enhance brand value and profit space.
5. Strengthen management, lay a solid foundation, and continuously improve the efficiency of group work
During the reporting period, the company continued to promote group management and control, and enhanced the company's strategic planning ability, policy analysis ability, scientific decision-making ability, investment and financing ability through the idea of "streamline administration, delegate power, strengthen regulation and improve services", and promoted the coordination among various business segments; Through comprehensive budget management and performance management, the company achieved target management, enhanced the awareness of indicators and responsibilities, and further focused on indicators and tasks and key tasks, which improved the company's management ability and work efficiency. In addition, according to the needs of the company's development, actively carry out the research, study and application of policies, establish and improve the system management system that meets the requirements of the company's development and internal control, optimize the corporate governance structure and management team personnel structure, build a professional, young, professional and international management team, and improve the scientific management level. At the same time, promote team building in various ways, enhance team cohesion and combat effectiveness, and ensure the steady implementation of the company's strategy.
6. Dig and spread corporate culture, and actively practice social responsibility
22 is the 37th anniversary of Jiuzhitang's founding. The company constantly digs into the internal value of the brand, focusing on the research, construction and publicity of corporate culture, enhancing employees' sense of honor and pride internally and continuously improving.